600 fully vaccinated vs coronavirus in Olongapo | Inquirer News

600 fully vaccinated vs coronavirus in Olongapo

Residents of Olongapo City returned to the vaccination site for their second dose of AstraZeneca. (PHOTO FROM OLONGAPO CITY INFORMATION OFFICE)

OLONGAPO CITY–After nearly three months of waiting, at least 600 residents here, who had been injected with the AstraZeneca vaccine for coronavirus, received their second dose on Wednesday (Aug. 4).

The vaccine recipients, who got their first dose on May 12, were among the latest to get fully vaccinated against SARS Cov2, the virus that causes COVID-19, according to the city information office.

Article continues after this advertisement

British-Swede pharmaceutical firm AstraZeneca recommends an interval of one month to three months between the first and second dose of its vaccine.

FEATURED STORIES

The country would receive more than 15 million doses of the AstraZeneca until 2022 through the COVAX Facility, a global initiative that aims to ensure equitable access to limited anti-COVID shots.

To date, Olongapo has already inoculated at least 23,000 residents on the priority list, mostly health workers, senior citizens and those with comorbidity.

Article continues after this advertisement

But only about 15,6000 of them were fully vaccinated, including those who were given the single-shot Janssen vaccine made by Johnson & Johnson. This was about eight percent of the target.

TSB

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: AstraZeneca, Olongapo City, second dose, Target, Vaccination

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.